NASDAQ:PCSA

Processa Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy PCSA

*Your capital is at risk

$2.15

+0.110 (+5.39%)

At Close: Jul 31, 2026

Processa Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 6.23B and sold 0 PCSA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	6.23B shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jul 16, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (100% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 15, 2026 Buy	Common Stock P-Purchase	Young David Pres. Research & Development	Officer	1 545 Value: $5K
Apr 15, 2026 Buy	Common Stock P-Purchase	Bigora Sian Chief Development Officer	Officer	1 799 Value: $5K
Apr 15, 2026 Buy	Common Stock P-Purchase	Skibsted Russell Chief Financial Officer	C-Suite Officer	1 984 Value: $6K
Mar 31, 2026 Buy	Common Stock P-Purchase	Ng George K Chief Executive Officer	CEO / President	2 136 Value: $5K
Mar 31, 2026 Buy	Common Stock P-Purchase	Neal James R Director	Director	789 Value: $2K
Mar 31, 2026 Buy	Common Stock P-Purchase	Baluch Khoso Director	Director	2 269 Value: $6K
Mar 31, 2026 Buy	Common Stock P-Purchase	Bigora Sian Chief Development Officer	Officer	2 107 Value: $5K
Mar 31, 2026 Buy	Common Stock P-Purchase	Young David Pres. Research & Development	Officer	1 810 Value: $5K
Mar 31, 2026 Buy	Common Stock P-Purchase	Skibsted Russell Chief Financial Officer	C-Suite Officer	2 324 Value: $6K
Mar 31, 2026 Buy	Common Stock P-Purchase	Pannu Geraldine Director	Director	2 072 Value: $5K
Mar 31, 2026 Buy	Common Stock P-Purchase	Ng George K Chief Executive Officer	CEO / President	2 136 Value: $5K
Mar 31, 2026 Buy	Common Stock P-Purchase	Lin Patrick Chief Business - Strategy Off	Officer	1 603 Value: $4K
Mar 31, 2026 Buy	Common Stock P-Purchase	Guy Wendy Chief Administrative Officer	Officer	1 854 Value: $5K
Jan 01, 2026 Buy	Common Stock M-Exempt	Bigora Sian Chief Development Officer	Officer	249 Value: $535
Jan 01, 2026 Buy	Restricted Stock Units M-Exempt	Guy Wendy Chief Administrative Officer	Officer	193 Value: $415
Jan 01, 2026 Buy	Common Stock M-Exempt	Guy Wendy Chief Administrative Officer	Officer	193 Value: $415
Jan 01, 2026 Buy	Common Stock M-Exempt	Lin Patrick Chief Business - Strategy Off	Officer	193 Value: $415
Jan 01, 2026 Buy	Common Stock M-Exempt	Lin Patrick Chief Business - Strategy Off	Officer	193 Value: $415
Jan 01, 2026 Buy	Restricted Stock Units M-Exempt	Young David Pres. Research & Development	Officer	49 Value: $105
Jan 01, 2026 Buy	Common Stock M-Exempt	Young David Pres. Research & Development	Officer	49 Value: $105
Jan 01, 2026 Buy	Restricted Stock Units M-Exempt	Bigora Sian Chief Development Officer	Officer	249 Value: $535
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Neal James R Director	Director	300 000 Value: $59.4K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Neal James R Director	Director	100 000 Value: $19.8K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Baluch Khoso Director	Director	300 000 Value: $59.4K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Baluch Khoso Director	Director	100 000 Value: $19.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROCESSA PHARMACEUTICALS INC.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selectiv...

Read Full Profile Here